AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Shattuck Labs to Present at 40th Annual Cowen Health Care Conference

February 25, 2020 GMT

AUSTIN, Texas--(BUSINESS WIRE)--Feb 25, 2020--

Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform to develop a novel class of biologic medicines for the treatment of cancer and other diseases, today announced that Shattuck Labs’ Chief Executive Officer, Taylor Schreiber, M.D., Ph.D., will present at the 40th Annual Cowen Health Care Conference on Wednesday, March 4 at 9:30 a.m. ET in Boston.

About Shattuck Labs, Inc.

Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform to develop a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and other diseases. The Company’s lead investigational new medicine SL-279252 (PD1-Fc-OX40L), a proprietary bi-functional fusion protein, has the potential to be a best-in-class therapy for solid tumors and lymphomas. Using its ARC™ platform, Shattuck is building a pipeline of therapeutics, that consolidate checkpoint blockade and TNF receptor agonists into single therapeutics to improve outcomes for patients. Shattuck has offices in Austin, Texas and Durham, North Carolina. For more information, please visit: http://www.shattucklabs.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200225005771/en/

CONTACT: Investor Contact:

Conor Richardson

Director of Finance

Shattuck Labs, Inc.

investors@shattucklabs.com

Media Contact:

Daniella Funaro

Stern Investor Relations, Inc.

212-362-1200

Daniella.Funaro@sternir.com

KEYWORD: UNITED STATES NORTH AMERICA TEXAS MASSACHUSETTS

INDUSTRY KEYWORD: RESEARCH INFECTIOUS DISEASES CLINICAL TRIALS OTHER HEALTH BIOTECHNOLOGY PHARMACEUTICAL HEALTH SCIENCE ONCOLOGY OTHER SCIENCE

SOURCE: Shattuck Labs, Inc.

Copyright Business Wire 2020.

PUB: 02/25/2020 11:09 AM/DISC: 02/25/2020 11:09 AM

http://www.businesswire.com/news/home/20200225005771/en